Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial. (June 2022)

• Record Type: Journal Article
• Authors: Miller, Ryan; Santangelo, Tess; Forghani-Arani, Farnoush; Rusthoven, Chad; Chen, Yingxuan; Castillo, Edward; Castillo, Richard; Guerrero, Thomas; Vinogradskiy, Yevgeniy
• Is Part Of: Radiotherapy and oncology. Volume 171(2022)
• Page Start: 22
• Page End: 24
• Publication Date: 2022-06
• Subjects: Lung cancer -- Functional imaging -- Cardiac toxicity; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2022.04.003
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: The authors of this manuscript have no other conflicts of interest to report. FDG-PET changes in the heart for lung cancer patients can predict clinical outcomes. Median overall survival for patients with a negative SUVmean cardiac change was 413 days. Median overall survival for patients with a positive SUVmean cardiac change was 585 days. Abstract: The purpose of this work was to use data from a large co-operative group trial to evaluate whether metabolic FDG-PET changes in the heart for lung cancer patients can predict for clinical outcomes. The study found that cardiac SUV changes following definitive chemoradiation are significantly (HR 0.811, 95% CI 0.68–0.96, p = 0.017) associated with overall survival in locally advanced NSCLC patients. If validated in a prospective cohort, our data show the potential for cardiac metabolic changes to be an early predictor for clinical outcomes.